Kiessling MK - Search Results

1

Mutant HRAS as novel target for MEK and mTOR inhibitors.

Kiessling MK, Curioni-Fontecedro A, Samaras P, Atrott K, Cosin-Roger J, Lang S, Scharl M, Rogler G. Kiessling MK, et al. Oncotarget. 2015 Dec 8;6(39):42183-96. doi: 10.18632/oncotarget.5619. Oncotarget. 2015. PMID: 26544513 Free PMC article.

2

Targeting the RAS pathway by mitogen-activated protein kinase inhibitors.

Kiessling MK, Rogler G. Kiessling MK, et al. Swiss Med Wkly. 2015 Dec 21;145:w14207. doi: 10.4414/smw.2015.14207. eCollection 2015. Swiss Med Wkly. 2015. PMID: 26691679 Free article. Review.

3

Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.

Kiessling MK, Curioni-Fontecedro A, Samaras P, Lang S, Scharl M, Aguzzi A, Oldrige DA, Maris JM, Rogler G. Kiessling MK, et al. PLoS One. 2016 Jan 28;11(1):e0147682. doi: 10.1371/journal.pone.0147682. eCollection 2016. PLoS One. 2016. PMID: 26821351 Free PMC article.

4

Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening.

Kiessling MK, Schuierer S, Stertz S, Beibel M, Bergling S, Knehr J, Carbone W, de Vallière C, Tchinda J, Bouwmeester T, Seuwen K, Rogler G, Roma G. Kiessling MK, et al. BMC Genomics. 2016 Sep 9;17(1):723. doi: 10.1186/s12864-016-3042-2. BMC Genomics. 2016. PMID: 27613601 Free PMC article.

5

Correction: Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.

Kiessling MK, Curioni-Fontecedro A, Samaras P, Lang S, Scharl M, Aguzzi A, Oldridge DA, Maris JM, Rogler G. Kiessling MK, et al. PLoS One. 2017 Jan 20;12(1):e0170851. doi: 10.1371/journal.pone.0170851. eCollection 2017. PLoS One. 2017. PMID: 28107499 Free PMC article.

6

A novel germline mutation of PDGFR-β might be associated with clinical response of colorectal cancer to regorafenib.

Rechsteiner M, Wild P, Kiessling MK, Bohnert A, Zhong Q, Stahel RA, Moch H, Curioni-Fontecedro A. Rechsteiner M, et al. Among authors: kiessling mk. Ann Oncol. 2015 Jan;26(1):246-248. doi: 10.1093/annonc/mdu471. Epub 2014 Oct 20. Ann Oncol. 2015. PMID: 25336117 Free article. No abstract available.

7

NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.

Kießling MK, Nicolay JP, Schlör T, Klemke CD, Süss D, Krammer PH, Gülow K. Kießling MK, et al. Oncotarget. 2017 Jul 11;8(28):45687-45697. doi: 10.18632/oncotarget.17669. Oncotarget. 2017. PMID: 28537899 Free PMC article.

8

Targeting ALK in Neuroendocrine Tumors of the Lung.

Akhoundova D, Haberecker M, Fritsch R, Höller S, Kiessling MK, Rechsteiner M, Rüschoff JH, Curioni-Fontecedro A. Akhoundova D, et al. Among authors: kiessling mk. Front Oncol. 2022 Jun 7;12:911294. doi: 10.3389/fonc.2022.911294. eCollection 2022. Front Oncol. 2022. PMID: 35756632 Free PMC article.

9

Efficacious and save use of biosimilar filgrastim for hematopoietic progenitor cell chemo-mobilization with vinorelbine in multiple myeloma patients.

Maul JT, Stenner-Liewen F, Seifert B, Pfrommer S, Petrausch U, Kiessling MK, Schanz U, Nair G, Mischo A, Taverna C, Schmidt A, Bargetzi M, Stupp R, Renner C, Samaras P. Maul JT, et al. Among authors: kiessling mk. J Clin Apher. 2017 Feb;32(1):21-26. doi: 10.1002/jca.21459. Epub 2016 Mar 22. J Clin Apher. 2017. PMID: 27001243

10

Targeting Secondary and Tertiary Resistance to BRAF Inhibition in BRAF V600E-Mutated Metastatic Colorectal Cancer.

Akhoundova D, Pietge H, Hussung S, Kiessling M, Britschgi C, Zoche M, Rechsteiner M, Weber A, Fritsch RM. Akhoundova D, et al. JCO Precis Oncol. 2021 Nov;5:1082-1087. doi: 10.1200/PO.21.00107. JCO Precis Oncol. 2021. PMID: 34994629 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25 results

Search Page

Filters